Literature DB >> 21325424

Marburg virus VP40 antagonizes interferon signaling in a species-specific manner.

Charalampos Valmas1, Christopher F Basler.   

Abstract

Marburgviruses are zoonotic pathogens that cause lethal hemorrhagic fever in humans and nonhuman primates. However, they do not cause lethal disease in immunocompetent mice unless they are adapted to this species. The adaptation process can therefore provide insight into the specific virus-host interactions that determine virulence. In primate cells, the Lake Victoria marburgvirus Musoke strain (MARV) VP40 matrix protein antagonizes alpha/beta interferon (IFN-α/β) and IFN-γ signaling by inhibiting the activation of the cellular tyrosine kinase Jak1. Here, VP40 from the Ravn strain (RAVV VP40)-from a distinct Marburg virus clade-is demonstrated to also inhibit IFN signaling in human cells. However, neither MARV nor RAVV VP40 effectively inhibited IFN-signaling in mouse cells, as assessed by assays of the antiviral effects of IFN-α/β and the IFN-α/β-induced phosphorylation of Jak1, STAT1, and STAT2. In contrast, the VP40 from a mouse-adapted RAVV (maRAVV) did inhibit IFN signaling. Effective Jak1 inhibition correlated with the species from which the cells were derived and did not depend upon whether Jak1 was of human or mouse origin. Of the seven amino acid changes that accumulated in VP40 during mouse adaptation, two (V57A and T165A) are sufficient to allow efficient IFN signaling antagonism by RAVV VP40 in mouse cells. The same two changes also confer efficient IFN antagonist function upon MARV VP40 in mouse cells. The mouse-adaptive changes did not affect the budding of RAVV VP40 in mouse cells, suggesting that this second major function of VP40 did not undergo adaptation. These data identify an apparent determinant of RAVV host range and virulence and define specific genetic determinants of this function.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21325424      PMCID: PMC3126248          DOI: 10.1128/JVI.02575-10

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  43 in total

1.  Structural characterization and membrane binding properties of the matrix protein VP40 of Ebola virus.

Authors:  R W Ruigrok; G Schoehn; A Dessen; E Forest; V Volchkov; O Dolnik; H D Klenk; W Weissenhorn
Journal:  J Mol Biol       Date:  2000-06-30       Impact factor: 5.469

2.  Nipah virus V protein evades alpha and gamma interferons by preventing STAT1 and STAT2 activation and nuclear accumulation.

Authors:  Jason J Rodriguez; Jean-Patrick Parisien; Curt M Horvath
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

3.  The Ebola virus VP35 protein functions as a type I IFN antagonist.

Authors:  C F Basler; X Wang; E Mühlberger; V Volchkov; J Paragas; H D Klenk; A García-Sastre; P Palese
Journal:  Proc Natl Acad Sci U S A       Date:  2000-10-24       Impact factor: 11.205

4.  A PPxY motif within the VP40 protein of Ebola virus interacts physically and functionally with a ubiquitin ligase: implications for filovirus budding.

Authors:  R N Harty; M E Brown; G Wang; J Huibregtse; F P Hayes
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-05       Impact factor: 11.205

5.  Tsg101 is recruited by a late domain of the nucleocapsid protein to support budding of Marburg virus-like particles.

Authors:  Olga Dolnik; Larissa Kolesnikova; Lea Stevermann; Stephan Becker
Journal:  J Virol       Date:  2010-05-26       Impact factor: 5.103

6.  Ebolavirus VP24 binding to karyopherins is required for inhibition of interferon signaling.

Authors:  Mathieu Mateo; St Patrick Reid; Lawrence W Leung; Christopher F Basler; Viktor E Volchkov
Journal:  J Virol       Date:  2009-11-04       Impact factor: 5.103

7.  The role of the Type I interferon response in the resistance of mice to filovirus infection.

Authors:  Mike Bray
Journal:  J Gen Virol       Date:  2001-06       Impact factor: 3.891

8.  Molecular characterization of guinea pig-adapted variants of Ebola virus.

Authors:  V E Volchkov; A A Chepurnov; V A Volchkova; V A Ternovoj; H D Klenk
Journal:  Virology       Date:  2000-11-10       Impact factor: 3.616

9.  Ebola virus matrix protein VP40 interaction with human cellular factors Tsg101 and Nedd4.

Authors:  Joanna Timmins; Guy Schoehn; Sylvie Ricard-Blum; Sandra Scianimanico; Thierry Vernet; Rob W H Ruigrok; Winfried Weissenhorn
Journal:  J Mol Biol       Date:  2003-02-14       Impact factor: 5.469

10.  Newcastle disease virus (NDV)-based assay demonstrates interferon-antagonist activity for the NDV V protein and the Nipah virus V, W, and C proteins.

Authors:  Man-Seong Park; Megan L Shaw; Jorge Muñoz-Jordan; Jerome F Cros; Takaaki Nakaya; Nicole Bouvier; Peter Palese; Adolfo García-Sastre; Christopher F Basler
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

View more
  43 in total

1.  Humanized Mice--A Neoteric Animal Disease Model for Ebola Virus?

Authors:  Joseph Prescott; Heinz Feldmann
Journal:  J Infect Dis       Date:  2015-11-17       Impact factor: 5.226

2.  Differential Regulation of Interferon Responses by Ebola and Marburg Virus VP35 Proteins.

Authors:  Megan R Edwards; Gai Liu; Chad E Mire; Suhas Sureshchandra; Priya Luthra; Benjamin Yen; Reed S Shabman; Daisy W Leung; Ilhem Messaoudi; Thomas W Geisbert; Gaya K Amarasinghe; Christopher F Basler
Journal:  Cell Rep       Date:  2016-02-11       Impact factor: 9.423

Review 3.  Innate immune evasion by filoviruses.

Authors:  Christopher F Basler
Journal:  Virology       Date:  2015-04-03       Impact factor: 3.616

4.  The ebolavirus VP24 interferon antagonist: know your enemy.

Authors:  Adrianna P P Zhang; Dafna M Abelson; Zachary A Bornholdt; Tong Liu; Virgil L Woods; Erica Ollmann Saphire
Journal:  Virulence       Date:  2012-08-15       Impact factor: 5.882

5.  Structural basis for Marburg virus VP35-mediated immune evasion mechanisms.

Authors:  Parameshwaran Ramanan; Megan R Edwards; Reed S Shabman; Daisy W Leung; Ariel C Endlich-Frazier; Dominika M Borek; Zbyszek Otwinowski; Gai Liu; Juyoung Huh; Christopher F Basler; Gaya K Amarasinghe
Journal:  Proc Natl Acad Sci U S A       Date:  2012-11-26       Impact factor: 11.205

6.  Natural History and Pathogenesis of Wild-Type Marburg Virus Infection in STAT2 Knockout Hamsters.

Authors:  Colm Atkins; Jinxin Miao; Birte Kalveram; Terry Juelich; Jennifer K Smith; David Perez; Lihong Zhang; Jonna L B Westover; Arnaud J Van Wettere; Brian B Gowen; Zhongde Wang; Alexander N Freiberg
Journal:  J Infect Dis       Date:  2018-11-22       Impact factor: 5.226

7.  Establishment and characterization of a lethal mouse model for the Angola strain of Marburg virus.

Authors:  Xiangguo Qiu; Gary Wong; Jonathan Audet; Todd Cutts; Yulian Niu; Stephanie Booth; Gary P Kobinger
Journal:  J Virol       Date:  2014-08-20       Impact factor: 5.103

Review 8.  Filovirus pathogenesis and immune evasion: insights from Ebola virus and Marburg virus.

Authors:  Ilhem Messaoudi; Gaya K Amarasinghe; Christopher F Basler
Journal:  Nat Rev Microbiol       Date:  2015-10-06       Impact factor: 60.633

9.  Impact of Měnglà Virus Proteins on Human and Bat Innate Immune Pathways.

Authors:  Caroline G Williams; Joyce Sweeney Gibbons; Timothy R Keiffer; Priya Luthra; Megan R Edwards; Christopher F Basler
Journal:  J Virol       Date:  2020-06-16       Impact factor: 5.103

10.  Inhibiting pyrimidine biosynthesis impairs Ebola virus replication through depletion of nucleoside pools and activation of innate immune responses.

Authors:  Priya Luthra; Jacinth Naidoo; Colette A Pietzsch; Sampriti De; Sudip Khadka; Manu Anantpadma; Caroline G Williams; Megan R Edwards; Robert A Davey; Alexander Bukreyev; Joseph M Ready; Christopher F Basler
Journal:  Antiviral Res       Date:  2018-08-23       Impact factor: 5.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.